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Abstract 
Background: The Vk*MYC transgenic and transplant mouse models of multiple myeloma (MM) are well established 
as a research tool for anti-myeloma drug discovery. However, little is known of the immune response in these models. 
Understanding the immunological relevance of these models is of increasing importance as immunotherapeutic 
drugs are developed against MM.
Methods: We set out to examine how cellular immunity is affected in Vk*MYC mouse models and compare that to 
the immunology of patients with newly diagnosed and relapsed/refractory MM.
Results: We found that there were significant immunological responses in mice developing either spontaneous 
(transgenic) or transplanted MM as a consequence of the degree of tumor burden. Particularly striking were the pro-
found B cell lymphopenia and the expansion of CD8+ effector memory T cells within the lymphocyte population that 
progressively developed with advancing disease burden, mirroring changes seen in human MM. High disease burden 
was also associated with increased inflammatory cytokine production by T lymphocytes, which is more fitting with 
relapsed/refractory MM in humans.
Conclusions: These findings have important implications for the application of this mouse model in the develop-
ment of MM immunotherapies.
Trial registration LitVacc ANZCTR trial ID ACTRN12613000344796; RevLite ANZCTR trial ID NCT00482261
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Background
Multiple myeloma (MM) is a malignancy of plasma cells 
that reside within a supportive niche in the bone marrow 
(BM) [1, 2]. The majority, if not all, patients have a pre-
malignant phase of monoclonal gammopathy of unde-
termined significance (MGUS) [3, 4]. With evolution of 
disease, patients variably develop organ damage that can 
result in lytic bone lesions, hypercalcaemia, renal failure 
and anaemia [1, 2]. Acquired immune paresis complicates 
advanced disease due to residual hypogammaglobulinae-
mia, B cell hypoplasia [5, 6], the effects of cumulative 
chemotherapies [7–9] and an ageing and exhausted T cell 
population [10, 11]. Although MM is largely incurable, 
the advent of immunomodulatory agents and protea-
some inhibitors has significantly increased the life expec-
tancy of patients with this disease [2, 12].
Numerous factors in MM are involved in the velocity 
of disease progression and they are acquired in a non-
stochastic but cumulative fashion over time [13]. These 
include immune-editing and oncogenic mutations, which 
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resistance to apoptosis. By utilizing knowledge of driver 
mutations, mouse models of disease have been devel-
oped. These mouse models are useful tools to study anti-
myeloma therapies; however, a deeper appreciation of 
their relevance to clinical disease is required. It is under-
stood that, unlike human MM, the mice used for these 
models are genetically uniform and the tumours often 
have a low mutational burden [14]. Less is known about 
the immunological similarities and differences between 
human disease and the Vk*MYC mouse models.
The Vk*MYC mouse model has been established as 
an investigative tool for anti-myeloma drug therapy [15, 
16]. The disease mechanism involves spontaneous AID-
dependent activation of MYC in post germinal B cells; 
an event that is not required for MM development in 
humans, although complex c-myc gene rearrangements 
and translocations often occur with disease progression 
[17]. It has been argued that there is no true “MGUS” 
period in the Vk*MYC model, rather the slow accumu-
lation of malignant cells [18]. Others have delineated a 
transition from “smoldering” to active myeloma period 
based on differences in BM vascularization [19].
It is also possible to induce a plasma cell malignancy 
in congenic C57BL/6 mice by transplanting cryopre-
served cells from the spleen of a diseased transgenic 
Vk*MYC mouse [16]. The advantage to this method is the 
greatly reduced time to disease state (weeks as opposed 
to 12–18  months with the transgenic model). However, 
the injected malignant cells are potentially quite different 
from their original BM resident counterparts, in that the 
transplanted model more readily develops extramedul-
lary disease.
Research using these models has been mainly concen-
trated on the development of new tumouricidal agents 
[16]; however, the role of the host immune response to 
malignancy is increasingly being realized, particularly in 
the context of immune therapies such as immunomodu-
latory drugs and checkpoint blockade inhibitors [20–22]. 
When assessing the role of novel immunomodulatory 
drugs in mouse models, it is important to understand 
their effects in context of the immune microenvironment.
We investigated the immunological relevance of dif-
ferent models of myeloma utilizing the Vk*MYC mouse 
and compared those findings to our analysis of T cells in 
human MM. In order to establish whether T cell aber-
rancies that are seen in relapsed/refractory disease are 
present in newly diagnosed MM, we analysed peripheral 
blood mononuclear cells (PBMCs) from patients with 
newly diagnosed MM (NDMM) and relapsed/refractory 
MM (RRMM), and compared with healthy blood donors 
from Australian Red Cross Blood Service (ARCBS). To 
evaluate whether the transgenic or transplant versions 
of the Vk*MYC mouse model would replicate our clini-
cal findings, we examined a cohort of aged transgenic 
Vk*MYC mice with spontaneous onset tumours and two 
of the more commonly used transplant clones in our lab-
oratory: Vk#4929 [16] and Vk#31.
We found that the immunological consequences of dis-
ease in the Vk*MYC mouse models were similar whether 
spontaneous onset (transgenic) or transplant mod-
els were used, providing that macroscopically evident 
extramedullary disease was not present. Advanced dis-
ease in these models replicated T cell fate most similar to 
that observed in RRMM; however, there may be a “win-
dow” with the transgenic Vk*MYC model that is compa-
rable to new-onset disease in humans.
Methods
Human samples and cells
All research was conducted in full conformance with 
principles of the “Declaration of Helsinki”, Good Clini-
cal Practice and within the laws and regulations of Aus-
tralia. Cryopreserved peripheral blood mononuclear 
cells (PBMCs) and bone marrow mononuclear cells 
(BMMCs) were analysed from MM patients enrolled in 
two clinical trials at baseline: LitVacc (ANZCTR trial 
ID ACTRN12613000344796, which recruited newly 
diagnosed, untreated patients), and RevLite (ANZCTR 
trial ID NCT00482261, which recruited relapsed/refrac-
tory patients). As a control group, PBMCs from ARCBS 
donors were used.
Mouse samples and cells
C57BL/6 mice were bred and housed at the Peter MacCa-
llum Cancer Center (PMCC) animal house. The studies 
were performed in accordance to PMCC Animal Ethics 
Committee approved procedures.
Transgenic Vk*MYC
BM and spleen were obtained from 15 transgenic 
Vk*MYC mice with six age-matched controls in two con-
secutive culls (14–18 months of age).
Transplant Vk*MYC
Vk#4929 and Vk#31 plasma cell clones were obtained 
from transgenic Vk*MYC mouse spleens and cryopre-
served. These clones were chosen based on experience 
of previous transplants where mice had a median sur-
vival of 8 and 14 weeks respectively. Recipient C57BL/6 
mice were injected via tail vein with approximately 
1–2  ×  105 cells. Mice were sacrificed once a notable 
monoclonal band (M-band) was present on serum pro-
tein electrophoresis and/or significant morbidity, which 
occurred at 12–16 weeks post-transplant (Vk#4929) and 
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11–19 weeks post-transplant (Vk#31). The results shown 
are representative data from two independent transplant 
cohorts for Vk#4929 and three consecutive culls from 
one transplant cohort for Vk#31, with six age-matched 
controls.
Cell preparation
Cell suspensions for flow cytometry were prepared by 
extracting BM from dissected bones, and the spleens 
were bluntly crushed in T cell media* before passing 
through a 40 μm filter. Cells were resuspended in T-cell 
media and aliquots of 5 × 106–1 × 107 cells were stained.
*T‑cell media
RPMI-1640 (Gibco) with 10  % foetal bovine serum, 
β-mercaptoethanol, non-essential amino acids, HEPES, 
Na-pyruvate, glutamax and penicillin/streptomycin.
Flow cytometry
Flow cytometry was performed using directly conjugated 
antibodies
Anti-human CD3ε (UCHT1, BD Biosciences), CD4 
(OKT3, Biolegend), CD8α (SK1, Biolegend), CD14 
(M5E2, Biolegend), CD19 (HIB19, Biolegend), CD27 
(0323, Biolegend), CD33 (IV M-505, Biolegend), CD45RA 
(HI100, Biolegend), CD57 (NK-1, BD Biosciences), pan-
TCRγδ (11F2, BD Biosciences), IFNγ (4S.B3, Biolegend) 
and IL17a (eBio64DEC17, eBioscience).
Anti-mouse TCRβ (H57-597, eBioscience), CD4 
(GK1.5, Biolegend), CD8α (53-6.7, eBioscience), CD19 
(1D3, BD Pharmingen), B220 (RA3-6B2, eBioscience), 
CD44 (IM7, BD Pharmingen), CD62L (MEL-14, BD 
Pharmingen), CD138 (281-2, Biolegend), IFNγ (XMG1.2, 
eBioscience) and IL-17A (TC11-18H10.1, Biolegend).
Fluorescence-minus-one (FMO), internal negative and/
or isotype controls were included to assist with gating.
Human Dead and irrelevant cells were excluded using 
Zombie Yellow viability dye (Biolegend) and CD14, CD19 
and CD33. Lymphocytes were then gated using forward 
and side scatter followed by doublet removal. Intracellu-
lar cytokine staining PBMC/BMMC were stimulated for 
4  h with PMA and ionomycin in the presence of mon-
ensin. Cells were harvested, surface stained and then 
permeabilised with Fix/Perm reagents (BD Bioscience) 
as per manufacturer’s instructions, prior to intracellular 
staining.
Mouse Lymphocytes were gated using forward and 
side scatter, followed by doublet and dead cell removal 
using Fixable Yellow (Invitrogen). Intracellular cytokine 
staining BMMC were stimulated for 4  h with 2  μl/ml 
Cell Stimulation Cocktail Plus Protein Transport Inhibi-
tors (eBioscience). Cells were harvested, surface stained 
and then permeabilised with Fix/Perm (BD Bioscience) 
as per manufacturer’s instructions, prior to intracellular 
staining.
Analysis was performed on BD LSR or BD LSR Fortessa 
cell analysers, and interpreted using FlowJo software 
(Treestar).
Cytometric bead array (CBA) assay
BM was extracted and suspended in 5  ml T cell media. 
After centrifugation, the supernatant was collected and 
stored at −20 °C. Cytokine analysis was performed using 
the BD mouse Th1/Th2/Th17 CBA kit as per manufac-
turer’s instructions.
Serum protein electrophoresis
Mouse serum was obtained by retro-orbital blood sam-
pling and serum gel electrophoresis was performed using 
the Hydasys 2 Scan (Sebia). An independent pathologist 
analysed the results.
Histopathology
BM trephines were prepared from dissected ster-
num from culled mice. These were fixed for 24 h in 4 % 
paraformaldehyde, and decalcified in 10  % EDTA for 
10–14 days. Paraffin embedded BM trephines were pre-
pared by the Petermac Microscopy and Histology Core 
Facility. CD138 immunohistochemistry was performed 
using rat anti-mouse CD138 antibody and biotin goat 
anti-rat immunoglobulin (BD Pharmingen) with strepta-
vidin-HRP and DAB staining.
Statistical analysis
Data was analysed using GraphPad Prism software. Sta-
tistical significance was determined using the Wilcoxon 
signed rank test (paired samples) or the Mann–Whitney 
test (unpaired samples) to compare two groups, or the 
student’s t test with the Holm-Sidak method applied for 
multiple comparisons. Pearsons correlation was used to 
calculate r2 values. *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Transgenic and transplant Vk*MYC mouse models show 
differing disease dynamics, but consistently develop B 
lymphopenia with advanced disease
MM patients requiring treatment for their disease have 
organ damage in the form of anaemia, renal failure and/
or lytic bone lesions, which has been shown to be rep-
licated in the Vk*MYC mouse models [16]. MM bone 
marrow infiltrates can be variable and do not necessarily 
directly correlate with end-organ damage; however, a BM 
plasma cell infiltrate of >50 % is considered high risk [23]. 
Serum protein electrophoresis, to identify paraprotein 
produced by the malignant cells, is often used as a sur-
rogate marker for BM disease progression or response to 
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treatment. Although human MM consists of heterogene-
ous clones [24], monoclonal banding is usual but one or 
more additional clones can develop in some with disease 
progression.
In order to establish comparisons with the human 
data, we elected to cull mice at time points when they 
were likely to have developed a significant burden of dis-
ease within the BM (described in “Methods” section). As 
anticipated, transgenic Vk*MYC mice had slow onset, 
relatively benign disease without major manifestations 
of end organ damage at the time of cull, whereas the 
transplanted mice characteristically exhibited rapidly 
progressive disease and clinical signs of distress. Mice 
transplanted with Vk#4929 variably developed bulky 
splenomegaly, sometimes with large plasmacytomas 
(Fig.  1a), or hind limb weakness. Flow cytometry con-
firmed extramedullary disease with an excess of plasma 
cells in the spleen (Fig. 1b).
Transgenic Vk*MYC mice developed oligoclonal band-
ing but, in some cases, one or two clones became domi-
nant over time forming monoclonal or biclonal bands 
(Fig. 1c). In contrast, the transplant clones (Vk#4929 and 
Vk#31) were picked because of their monoclonality, and 
a replicative monoclonal band was seen in all mice trans-
planted. Bone marrow histology also differed, with trans-
genic mice tending to have patchy BM infiltrates (Fig. 1d, 
middle) as compared to transplanted mice that more 
often had diffuse BM infiltrates (Fig. 1d, right).
We used this information to divide the mice into 
groups based on grade of disease: low grade disease was 
defined as a BM plasma cell infiltrate of 10–30 %, inter-
mediate disease 30–50 % and high grade disease ≥50 % 
plasma cell infiltrate (and/or the presence of extramed-
ullary disease). In keeping with the clinical features, 
transgenic mice had low-intermediate grade disease but 
the transplanted mice usually had high-grade disease 
(Fig. 2a).
In both BM and spleen there was a progressive reduc-
tion in the proportion of B cells in all Vk*MYC subtypes 
with increasing tumour burden, that reached signifi-
cance with high-grade disease (Fig. 2b, c). This is consist-
ent with data shown in human clinical cohorts of MM, 
where a profound B lymphopenia has been described in 
both newly diagnosed and relapsed MM [5, 6]. There was 
a significant increase in the proportion of T cells in trans-
plant Vk#31 with high-grade disease in the BM, but not 
the spleen, suggesting that this may not purely be a recip-
rocal change due to B lymphopenia (Fig. 2b, c right). On 
the other hand, there was a simultaneous reduction in the 
proportion of T cells in the spleen of transplant Vk#4929 
with high-grade disease, reflecting the splenic plasma cell 
infiltrate seen in this model (Fig. 2b, c middle).
Comparison of CD4+ and CD8+ T lymphocyte populations 
in human MM and the Vk*MYC mouse models
Our group has previously shown that patients with 
RRMM have marked CD4+ T lymphopenia that does 
not recover with lenalidomide/dexamethasone therapy 
[25]. To determine whether this is also true in newly 
diagnosed MM, we analysed PBMCs from NDMM and 
RRMM patients, and compared with healthy donors.
We show that there was a decrease in both the abso-
lute number and proportion of CD4+ T lymphocytes in 
RRMM (accompanied by a reciprocal increase in CD8+ 
T lymphocytes) that was not present in NDMM (Fig. 3a). 
NDMM patients had a comparable CD4+/CD8+ T cell 
profile to that of healthy donors (Fig.  3a right), which 
were derived from blood donors with normal white cell 
counts. As expected, BM samples from NDMM patients 
showed a decreased CD4:8 ratio compared with PB 
(Fig. 3b).
BM T lymphocyte populations appeared unaltered in 
transgenic Vk*MYC and transplant Vk#4929, but there 
were notable changes occurring in transplant Vk#31 with 
high-grade disease (Figs. 2b, 3c). As discussed previously, 
the increase in % T lymphocytes in Vk#31 with high 
grade disease could represent a reciprocal change to the 
B lymphopenia occurring (Fig. 2b); however, the change 
in CD4:CD8 ratio with high-grade disease suggested 
a preferential expansion of CD8+ T cells and/or loss of 
CD4+ T cells (Fig. 3c).
Advanced disease is associated with increased 
inflammatory cytokine production
Th17 cells have been shown to be increased in the PB 
and BM microenvironment of patients with MM com-
pared to normal, as well as elevated levels of IL-17, Th17-
polarising cytokines [26–28] and IFNγ [28] in the BM. 
We found significantly increased IFNγ-producing CD4+ 
and CD8+ T lymphocytes and (to a much lesser degree) 
increased IL-17A-producing CD4+ T lymphocytes in 
PBMC samples from patients with RRMM compared to 
levels seen in NDMM or healthy controls (Fig.  4a). The 
proportion of cytokine-producing T lymphocytes was 
comparable between PBMC and BMMC from NDMM 
patient samples (Fig. 4b).
In Vk#31, but not transgenic Vk*MYC mice, there was 
a trend towards increased IFNγ- and IL17A-producing 
CD4+ T lymphocytes in high-grade disease (Fig.  4c(i)). 
IFNγ-producing CD8+ T lymphocytes increased with 
disease burden in both mouse models, but were only 
significantly higher in Vk#31 with high-grade disease 
(Fig.  4c(ii)). Increased IFNγ was also evident in BM 
supernatants from Vk#31 as compared with controls; no 
significant difference was noted in IL17A levels (Fig. 4d). 
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Increased inflammatory cytokine production was not 
seen in transplant Vk#4929 with high-grade disease (data 
not shown).
Shifts within memory T cell subsets, evident from first 
diagnosis in human MM, are replicated in the transgenic 
Vk*MYC mouse model
Shifts within T cell subset populations have been 
described in ageing populations [10, 29, 30] and in 
patients with chronic inflammation or malignancy [31]. 
In both cases, naïve T cells are depleted with reciprocal 
accumulation of variably described “antigen-experienced 
cells” (namely effector memory T (TEM) cells or termi-
nally differentiated effector memory T (TEMRA) cells) that 
share characteristics of an exhausted phenotype and low 
proliferative capacity.
To investigate whether similar changes in T cell pro-
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Fig. 1 Disease characteristics of the transgenic and transplant Vk*MYC models. a Dissected spleen (left) wild type control (right) diseased Vk#4929 
with a large plasmacytoma (arrow). b Plasma cells in the spleen of wild type and diseased Vk*MYC mice. Representative FACS plot is shown to the 
left: plasma cells are defined as CD138+B220− events and expressed as % viable cells. c Serum protein electrophoresis in individual mice at time of 
cull: (i) Transgenic Vk*MYC showing predominantly oligoclonal banding in the gamma region. (ii) Transplant Vk#4929 and Vk#31 showing monoclo-
nal banding in the fast or slow gamma regions respectively. d BM trephine immunohistochemistry. Left CD138 staining showing normal numbers 
of plasma cells in wild type control. Middle H&E showing patchy plasma cell infiltrate in transgenic Vk*MYC (arrow). Right CD138 staining showing a 
diffuse infiltrate of plasma cells in transplant Vk#31
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memory subsets, using CCR7 and CD45RA to describe 
naïve (TN), central memory (TCN), effector memory 
(TEM) and terminally differentiated effector memory 
(TEMRA) T cell memory subsets. We showed that in 
RRMM patients there were significant changes in the 
memory T cell profile, with a marked reduction in the 
proportion of CD4+ and CD8+ TN cells and expansion 
of TEM cells (and CD8+ TEMRA) within the lymphocyte 
population (Fig.  5a). Unlike the CD4+ T lymphopenia 
and increased cytokine production seen in RRMM, these 
changes were also already present in NDMM, in particu-
lar within the CD8+ T cell population. T cell subsets were 
broadly comparable between PBMC and BMMC sam-
ples from NDMM patients, except that TEMRA made up a 
larger proportion and TCM a smaller proportion of BM as 





Low Plasma cell BM infiltrate 10-30%
Intermediate Plasma cell BM infiltrate 30-50%





















































































































































































































































Fig. 2 Disease characteristics of the transgenic and transplant Vk*MYC models. a Bar graph depicting grade of disease in the Vk*MYC mouse 
models. b BMMC lymphocyte analysis in Vk*MYC mouse models: Box and whisker plots showing B lymphocyte (top) and T lymphocyte (bottom) 
populations. B cells are identified as B220+CD19+ events and T cells are identified as TCRβ+B220− events, and are expressed as % viable cells from 
the FS/SS lymphocyte gate. (Left) Transgenic Vk*MYC (middle) Transplant Vk#4929 (right) Transplant Vk#31. Closed circles represent age-matched wild 
type control (a-m WT), open circles represent diseased mice [which are subdivided into low, intermediate (int.) or high-grade disease as described in 
a]. c Splenic lymphocyte analysis in Vk*MYC mouse models: Box and whisker plots (as described for b)
Mirroring the human findings, in transgenic Vk*MYC 
BMMC, there was a reduction in the proportion of TN 
(and TCN in the mouse model) with an increase in TEM 
within the CD4+ and CD8+ T lymphocyte populations 
with disease progression (Fig. 5c). The expansion of TEM 
within the CD8+ T cell population was most apparent 
(Fig.  5c(iii)) and is likely to account for increased IFNγ 
expression from CD8+ T cells; indeed there was a corre-
lation between the two (Fig. 5d). Similar changes in the 
CD8+, but not CD4+, T memory cell profile were noted 
in a diseased cohort of transplant Vk#4929 (Fig. 5e).
Markers of T cell exhaustion are altered in human MM 
patients, even at first diagnosis
We additionally analysed levels of the co-stimulatory 
molecule CD27 and the senescence-associated marker 
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CD57, which have been shown to be altered in CD8+ 
T lymphocyte populations in elderly individuals [10, 
29, 30] and in MM [32, 33]. In NDMM and, most nota-
bly, RRMM patients, CD8+ T cells exhibited reduced 
CD27 expression and increased CD57 in keeping with 
an increasing proportion of antigen experienced T cells. 
These changes were also seen in CD4+ T cells in RRMM 
(Fig.  6a). BM CD4+ T cells demonstrated lower CD27 
and higher CD57 levels than PB CD4+ T cells (Fig. 6b(i)) 
that is likely explained by the larger proportion of TEMRA 
in BM (Fig.  5b(i)). BM CD8+ T cells exhibited slightly 
lower CD27 levels but equivalent levels of CD57.
Discussion
We set out to compare T cell profiles in NDMM and 
RRMM, and to establish whether the immunology is 
replicated in the Vk*MYC mouse models. Our analysis 
of patient samples illustrates that the lymphocyte profile 
is already changing at the time of diagnosis of MM, with 
the development of B lymphopenia [5, 6] and a shift in 
the T cell profile from a predominantly naïve to a pre-
dominantly antigen-experienced TEM/TEMRA cell popula-
tion (Fig. 5), associated with markers of T cell exhaustion 
(Fig. 6). These aberrancies are even more apparent with 
progression to RRMM; however, significant additional 
immunological changes have occurred that include CD4+ 
T lymphopenia [8] and increased inflammatory cytokine 
production (Fig. 4).
This established a baseline against which the immu-
nology of mouse models could be compared; though we 
acknowledge that, because of pragmatic limitations with 
the availability of both PB and BM human MM samples, 
direct comparison with murine BM may not fully address 



























































































































































































































































Fig. 3 CD4+/CD8+ T lymphocyte analysis in human MM and Vk*MYC mouse models. a Human PBMC CD4+/CD8+ T lymphocyte analysis. (i) FACS 
plots showing representative staining: CD4+/CD8+ T cells are expressed as % αβ T cells (CD3ε+ TCRγδ− events). (ii–iii) Box and whisker plots show-
ing (ii) CD4+ T cells and (iii) CD8+ T cells as an absolute number (left) and as a proportion of αβ T cells (right). Clear boxes ARCBS donors, light grey 
boxes NDMM, dark grey boxes RRMM. b Human T lymphocyte matched pair analysis of PBMC and BMMC samples in NDMM (as described for a). c 
Murine BMMC CD4+/CD8+ T lymphocyte analysis in Vk*MYC mouse models. (i) FACS plots showing representative staining: CD4+/CD8+ T cells are 
expressed as % T cells (TCRβ+B220− events). (ii–iii) Box and whisker plots showing (ii) CD4+ T cells (iii) CD8+ T cells. (Left) Transgenic Vk*MYC (middle) 
Transplant Vk#4929, (right) Transplant Vk#31. Closed circles represent a-m WT, open circles represent diseased mice [which are subdivided into low, 
intermediate (int.) or high-grade disease as described in Fig. 2a]



















































































































































































































































































Fig. 4 T lymphocyte intracellular cytokine staining in human MM and Vk*MYC mouse models. a Human PBMC CD4+/CD8+ T lymphocyte intracel-
lular cytokine staining (ICS). Box and whisker plots showing (i) % IFNγ+ (top) and % IL-17A+ (bottom) expressing CD4+ T lymphocytes (ii) % IFNγ+ 
expressing CD8+ T cells. Clear boxes ARCBS donors, light grey boxes NDMM, dark grey boxes RRMM. b ICS matched pair analysis in PBMC and BMMC 
samples in NDMM (as described for a). (i) % IFNγ+ (top) and % IL-17A+ (bottom) expressing CD4+ T lymphocytes (ii) % IFNγ+ expressing CD8+ T cells. 
c Murine BMMC CD4+/CD8+ T lymphocyte ICS in Vk*MYC mouse models. Box and whisker plots showing (i) % IFNγ+ (top) and % IL17+ T cells (bot-
tom) expressing CD4+ T lymphocytes (ii) % IFNγ+ expressing CD8+ T cells. (Left) Transgenic Vk*MYC, (Right) Transplant Vk#31. Closed circles represent 
a-m WT, open circles represent diseased mice (which are subdivided into low, intermediate (int.) or high-grade disease as described in Fig. 2a). d 
Box and whisker plots showing IFNγ (top) and IL17 (bottom) concentration in BM supernatants from transplant Vk#31 and age-matched WT controls 
by cytometric bead array (CBA) analysis
(See figure on next page.) 
Fig. 5 T cell memory subset analysis in human MM and Vk*MYC mouse models. a Human PBMC CD4+/CD8+ T cell memory subset analysis. (i–ii) 
Box and whisker plots showing T cell memory subsets (i) CD4+ T cells (ii) CD8+ T cells. FACS plots showing representative staining are shown to 
the left: T cell subsets are expressed as %CD3ε+CD4+ or %CD3ε+CD8+ T cells and are defined as naïve/TN (CD45RA
+CCR7+), central memory/TCM 
(CD45RA−CCR7+), effector memory/TEM (CD45RA
−CCR7−), and terminally differentiated effector memory T cells/TEMRA (CD45RA
+CCR7−). Clear 
boxes ARCBS donors, light grey boxes NDMM, dark grey boxes RRMM. b T cell memory subset matched pair analysis in PBMC and BMMC from NDMM 
patients (as described in a). (i) CD4+ T cells (ii) CD8+ T cells. c Murine BMMC T cell memory subset analysis in transgenic Vk*MYC. (i) FACS plots 
showing representative staining: T cell subsets are expressed as %TCRβ+CD8+ or %TCRβ+CD8− (CD4+) and are defined as naïve/TN (CD44
−CD62L+), 
central memory/TCM (CD44
+CD62L−) and effector memory/TEM (CD44
+CD62L−). (ii–iii) Box and whisker plots comparing WT to diseased transgenic 
Vk*MYC. (ii) CD4+ T cells (iii) CD8+ T cells. Closed circles represent a-m WT, open circles represent diseased mice (which are subdivided into low, 
intermediate (int.) or high-grade disease as described in Fig. 2a). d Dot plot showing correlation between %CD8+ TEM and %IFNγ
+CD8+ T cells in 
transgenic Vk*MYC mice. e Murine BMMC T cell memory subset analysis in a diseased cohort of transplant Vk#4929 (flow cytometry as described for 
c). Clear boxes/closed circles represent a-m WT, dark grey boxes/open circles represent diseased mice
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BM inflammatory T cell profiles have been mirrored in 
PB [28, 34], and we have shown broadly similar T cell 
profiles in PB and BM in NDMM samples (Figs. 4b, 5b).
In our analysis of the mouse models and other 
published data [19, 35] we found that, regardless of 
whether it is the transgenic or transplant version of 
Vk*MYC, the amount of BM disease appears to be a 
critical factor in determining changes to cellular immu-
nity. In all Vk*MYC mouse models, increasing tumour 
burden was associated with a progressive B lymphope-
nia (Fig. 2b, c); however, alterations in the T cell profile 
differed. High-grade disease in transplant Vk#31 was 
clearly associated with an inflammatory CD8+ T cell 
profile, reminiscent of RRMM. This might have been 
replicated in the transgenic Vk*MYC mice had there 
been a higher burden of disease: Calcinotto et  al. [19] 
described BM accrual of CD4+ and CD8+ T lympho-
cytes and an inflammatory T cell profile in the trans-
genic Vk*MYC model, which could be explained by 
the higher BM plasma cell infiltrates (i.e. 40–80  %) in 
their cohort as compared to ours (i.e. 30–50  %). The 
lack of any inflammatory T cell response in transplant 
Vk#4929 might be explained by the fact that it is a very 
aggressive clone that causes rampant extramedullary 
disease and may not allow time for the usual immune 
aberrancies to develop. In line with this observation, 
another group described CD8+ T lymphopenia devel-
oping in mice transplanted with an aggressive Vk*MYC 
clone (mice needed to be culled by 5 weeks post-trans-
plant) [35]. There is also the suggestion that inflamma-
tion wanes with end-stage disease [35] or is replaced by 
a Th2 response [19].
The Vk*MYC model most successfully replicates 
changes within the memory T cell population, i.e. from 
a predominantly naïve to predominantly effector T 
cell population, observed in patients with MM (Fig.  5) 
and with advancing age [10]. This is noteworthy in the 
tumour setting, as effector memory CD8+ T cells have 
been shown to exhibit inferior anti-tumour immunity 
to central memory CD8+ T cells [36], despite being effi-
cient IFNγ producers [37]. Similar findings were recently 
reported in another mouse model of chronic haemato-
logical malignancy [38]: in the Eμ-TCL1 mouse model 




























































































Fig. 6 CD27/CD57 expression analysis in human MM. a Human PBMC CD4+/CD8+ T cell analysis of CD27 and CD57 expression. Box and whisker 
plots showing % CD27+ (left) and  % CD57+ (right) of (i) CD4+ T cells and (ii) CD8+ T cells. Clear boxes ARCBS donors, light grey boxes NDMM, dark grey 
boxes RRMM. b CD27 and CD57 expression matched pair analysis in PBMC and BMMC from NDMM patients (as described in a). (i) CD4+ T cells (ii) 
CD8+ T cells
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described the expansion of IFNγ-producing CD8+ T cells 
in ageing transgenic mice, and effector memory T cells 
(at the expense of naïve T cells) in normal and transgenic 
ageing mice, as well as mice adoptively transplanted 
with CLL. They also reported aberrant PD1 expression 
on CD44+CD3+CD8+ T cells, suggesting an exhausted 
phenotype.
Appreciating T cell populations and their fate with pro-
gressive disease is essential to understanding immune 
evasion by malignancies, but is also very relevant in 
mouse models that are used in a translational capacity 
to develop novel therapies. It is likely that immunothera-
peutic treatments, which rely on the presence of a T and 
NK cell response, have therapeutic “windows” through-
out the natural progression of MM, i.e. some treatments 
might be better utilized earlier in the course of disease 
before T cell immunosenescence has occurred.
We suggest that there may be a “window” akin to 
NDMM for testing immunomodulatory drug therapies 
in the transgenic Vk*MYC model, but the transplant 
Vk#31 model and advanced disease in the transgenic 
Vk*MYC model more accurately replicate the T cell 
immune microenvironment of RRMM (or even end-
stage disease in transplant Vk#4929). The fact that the 
Vk*MYC mouse model most closely correlates with 
RRMM is perhaps not so surprising, given that it relies 
on the overexpression of the MYC oncogene that is 
more commonly associated with advanced human MM. 
Of notable interest, it was recently demonstrated in a 
mouse model of MYC-induced T cell acute lymphoblas-
tic leukaemia, that MYC could regulate the expression 
of two immune checkpoint inhibitors, CD47 and PD-L1, 
on the tumour cell surface and thereby suppress CD4+ 
T cell, CD69+ activated T cell and F4/80+ macrophage 
recruitment [39].
There is clearly much more to be learnt about the 
immunology of MYC-driven malignancies, beyond its 
role in tumourigenesis. However, in the Vk*MYC mouse 
models, we would suggest that the most appropriate role 
for testing immunomodulatory therapies is likely to be 
in RRMM that remains an area of clinical need for novel 
therapies.
Conclusions
Our findings indicate that T cell profiles differ in patients 
with newly diagnosed MM from that seen in advanced 
MM. Advanced disease in transgenic and transplanted 
Vk*MYC mouse models of MM more closely mirrors 
the immunology of patients with RRMM rather than 
NDMM. This is an important consideration when inter-
preting the pre-clinical findings of therapies tested in the 
Vk*MYC mouse model.
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